GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange that Record date for the purpose of Dividend is 29-May-2026.
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GlaxoSmithKline Pharmaceuticals reported FY2026 annual results with consolidated revenue of Rs. 3,82,167 lakhs, up 1.9% from Rs. 3,74,921 lakhs in FY2025. Profit after tax grew 11.7% to Rs. 1,03,598 lakhs from Rs. 92,758 lakhs. Standalone PAT was Rs. 1,01,182 lakhs, up 10.1% from Rs. 91,906 lakhs. EPS improved to Rs. 59.73 (standalone) and Rs. 61.15 (consolidated) from Rs. 54.24 and Rs. 54.76 respectively. The Board recommended a final dividend of Rs. 57 per share (up from Rs. 54 total dividend in FY2025), with record date May 29, 2026 and payment after July 1, 2026. Auditors issued unmodified (clean) opinions. Exceptional items of Rs. 2,062 lakhs (consolidated) included profit from property and land sales. New labour codes impacted employee costs by Rs. 1,182 lakhs.
The company showed solid profit growth despite modest revenue expansion. Increased dividend signals confidence. Cash position strengthened with Rs. 1,10,205 lakhs in cash (consolidated). Clean audit and positive cash flows are positive for shareholders.